uploads///ALXN

Alexion’s Soliris Continues to See Growth

By

Updated

Soliris

Alexion Pharmaceuticals’ (ALXN) products on the market include Soliris, Strensiq, and Kanuma. Alexion’s Soliris, a humanized monoclonal antibody, is targeted for treating inflammation associated with chronic disorders in hematology, nephrology, and neurology.

Total Soliris sales increased from $813.3 million in the second quarter of 2017 to $898.2 million. The majority of this growth came from its US sales, which increased from $317.8 million in the second quarter of 2017 to $395.8 million in the second quarter of 2018. Its Europe and Asia-Pacific sales also increased from $248.5 million and $80.8 million, respectively, during the second quarter of 2017 to $253.4 million and $93.6 million, respectively, in the second quarter of 2018. Soliris sales in the rest of the world region, on the other hand, decreased by $10.8 million to $155.4 million in the second quarter of 2018.

Article continues below advertisement

Strensiq

Alexion’s Strensiq, a targeted enzyme replacement therapy, is approved for treating hypophosphatasia (or HPP), which is an ultra-rare genetic and progressive metabolic disease characterized by defective bone mineralization that may lead to deformity of bones and other skeletal abnormalities.

Alexion Pharmaceuticals’ Strensiq generated total revenues of $125.1 million in the second quarter of 2018 as compared with $83.6 million in the second quarter of 2017. Its US revenues increased from $70 million in the second quarter of 2017 to $99.9 million in the second quarter of 2018. Strensiq sales from Europe and Asia-Pacific increased from $8.6 million and $4.4 million, respectively, during the second quarter of 2017 to $16.4 million and $6.3 million, respectively, in the second quarter of 2018. Strensiq sales from the company’s rest of world region increased from $600,000 in the second quarter of 2017 to $2.5 million in the second quarter of 2018.

We take a look at sales of Alexion Pharmaceuticals’ Kanuma and its acquisition of Wilson Therapeutics in the next part.

Advertisement

More From Market Realist